진학프로석·박사 채용 접수 플랫폼

The Josep Carreras Leukaemia Research Institute (IJC) is a comprehensive cancer researchcenter dedicated to conduct research and drive innovation in the epidemiological, preventive, clinical, translational, and basic aspects of leukaemia and other hematologic malignancies, with the final aim of finding a cure for these diseases. It was created in 2010, and since then has experienced exponential growth.

The IJC is also part of the network of Excellence Research Centers of Catalonia (CERCA) and was accredited as a Severo Ochoa Center of Excellence by the Ministry of Science, Innovation, and Universities in 2024. Since 2018, the Institute has also been accredited by the Scientific Foundation of the Spanish Association Against Cancer (FCAECC) Additionally, IJC is one of the centers integrated into the Institut de Recerca Germans Trias i Pujol (IGTP) accreditation as Accredited Health Research Institute (IIS) by the Carlos III Health Institute (ISCIII).

The IJC's main headquarters is located within the Can Ruti Biomedical Campus, alongside other leading biomedical institutions, providing direct access to cutting-edge scientific and technological facilities, as well as complementary community services. The IJC has six locations integrated into reference hospitals: Hospital Germans Trias i Pujol, Hospital Clínic, Hospital Sant Pau, Hospital Trueta, Hospital del Mar and Hospital San Joan de Déu. This facilitates close collaboration between basic and clinical researchers, fostering translational research that integrates basic science with clinical practice in clinical settings.

The Josep Carreras Leukemia Research Institute is looking for a Group Leader for our Can Ruti Campus to open a new research line focused on improving the quality of life of hematological cancer patients.

RESEARCH DESCRIPTION

With the ambition of positioning IJC as a European leader in survivorship research in hematologic malignancies, we are launching a new programme centred on patient‑ and caregiver‑reported outcomes, neurocognitive trajectories, and digitally enabled supportive‑care interventions. We are particularly interested in advancing survivorship science by developing caregiver reported outcome measures, designing and testing multidisciplinary and behavioural interventions to improve quality of life, and leveraging real‑world data and digital health tools to monitor long‑term effects in the era of CAR‑T and other cellular therapies. The successful candidate will shape this agenda and build global collaborations that translate evidence into clinical practice.

This position is funded by the Severo Ochoa funds associated to the accreditation of excellence (CEX2023-001258-S) by the Ministerio de Ciencia, Innovación y Universidades - Agencia Estatal de Investigación (MCIN/AEI/10.13039/501100011033).